Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar

Webinar will include a review of full-year 2025 and fourth quarter 2025 financial results, a deep dive into the equine veterinary market and Zomedica's equine-focused product portfolio, along with a live Q&A session.

ANN ARBOR, MI / ACCESS Newswire / March 10, 2026 / Zomedica Corp. (OTCQB:ZOMDF), a veterinary health company offering advanced diagnostic and therapeutic solutions for equine and companion animals, today announced that its upcoming "Fourth Friday at Four" investor webinar will include a review of its fourth quarter and full year 2025 financial results along with a deep dive into the equine veterinary marketplace, highlighting the size of the market opportunity and the products and experts supporting Zomedica's growing presence in the segment.

The live webinar will take place Friday, March 27, 2026 at 4:00 p.m. ET and will feature members of Zomedica's leadership team and equine specialists discussing Zomedica's 2025 financial results, the economic scale of the equine industry, the veterinary needs within the market, and how Zomedica's technologies are positioned to serve equine practitioners, followed by an interactive question and answer session.

The equine industry represents a significant global economic ecosystem, with the U.S. horse industry alone contributing approximately $122 billion annually to the U.S. economy, according to the American Horse Council Foundation's Economic Impact Study of the U.S. Horse Industry. Globally, the equine population is estimated to exceed approximately 60 million horses worldwide, based on data compiled by the Food and Agriculture Organization of the United Nations (FAO) and World Horse Welfare, underscoring the scale of veterinary care required to support equine health.

Spending on performance and sport horses further highlights the size of the opportunity. Studies of competitive equestrian disciplines indicate that annual care and training expenses for sport horses can range from approximately $25,000 to more than $100,000 per horse per year, depending on discipline and level of competition, according to industry data from the American Horse Council and Fédération Equestre Internationale (FEI). This level of investment in equine athletes continues to drive demand for advanced veterinary diagnostics and therapeutic technologies.

During the webinar, investors will gain insight into how Zomedica's portfolio aligns with key clinical needs in equine medicine, including:

• Point-of-care endocrine diagnostics using the TRUFORMA® diagnostic platform to support rapid clinical decision-making in the veterinary clinic

• Advanced regenerative therapies and shock wave technologies, including PulseVet® shock wave therapy, widely recognized as the gold standard in electrohydraulic shock wave therapy and the most studied shock wave technology in the equine field for treating musculoskeletal injuries in performance horses

• Pulsed electromagnetic field (tPEMF) therapy using the Assisi EquiLoop™ device designed to support healing, pain management, and recovery in equine patients

• Emerging diagnostic technologies such as TRUVIEW® digital cytology designed to enhance diagnostic insight within veterinary practices

• VETIGEL® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, for use both by veterinarians and horse owners

"Equine medicine represents a meaningful opportunity within veterinary health, supported by a passionate global community of owners, trainers, and veterinarians who demand advanced clinical tools," said Trudy Gage, Zomedica's Vice President, Equine Sales & Client Education. "This Fourth Friday at Four session will give investors a closer look at the size of the equine market, the specialists who serve it, and how Zomedica's expanding portfolio of diagnostic and therapeutic solutions is positioned to participate in this high-value segment of animal health."

The discussion will also explore the growing need for rapid endocrine diagnostics in equine medicine. Pituitary pars intermedia dysfunction (PPID), commonly known as equine Cushing's disease, is estimated to affect up to 20-25% of horses over age 15, according to research published in the Journal of Veterinary Internal Medicine, creating consistent demand for accurate endocrine testing within equine veterinary practices. Related metabolic disorders such as equine metabolic syndrome (EMS), which are commonly associated with insulin dysregulation and increased laminitis risk, further reinforce the importance of reliable insulin testing as part of routine endocrine screening and management in horses.

Participants will also gain insight into the broader veterinary diagnostics market, which provides important context for the equine opportunity. Industry analyses from MarketsandMarkets and Grand View Research project the global veterinary diagnostics market will exceed $10 billion by the end of the decade, driven by increasing demand for rapid point-of-care testing in veterinary clinics. Within that broader market, equine diagnostics represents a specialized but important segment, particularly for endocrine disorders, metabolic disease, and performance medicine.

Within the equine segment specifically, the global equine veterinary services market represents a multi-billion-dollar opportunity, supported by increasing investment in sport horse medicine, performance diagnostics, and advanced therapeutic technologies, according to industry analyses from Global Market Insights and Allied Market Research.

The webinar will provide investors with a behind-the-scenes look at the products, people, and clinical expertise supporting Zomedica's presence in the equine segment and how these initiatives align with the company's broader strategy to expand revenue opportunities while moving toward sustained profitability.

The program will conclude with a discussion of Zomedica's full-year 2025 financial results as well as highlights from the company's fourth quarter 2025 earnings performance, followed by a live question-and-answer session .

Event Details

Title: Fourth Friday at Four - The Equine Veterinary Market Opportunity
Date: Friday, March 27, 2026
Time: 4:00 p.m. Eastern Time
Registration: https://itl.ink/March2026

A replay of the webinar will be available following the event on the Investor Relations section of the Zomedica website.

About Zomedica

Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® line of therapeutic devices, the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VETGuardian Plus^ÔZero Touch monitoring system, and VETIGEL® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, each designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts:http://investors.zomedica.com

• LinkedIn:https://www.linkedin.com/company/zomedica

• Facebook:https://m.facebook.com/zomedica

• Instagram:https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including adoption of our AI technology for microscopy, and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
Investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.